{"result": "(\"entity\"<|>LNAA<|>ORGANIZATION<|>LNAA is a therapeutic option that is effective for patients with poor adherence to diet in the context of phenylketonuria (PKU).)\n##\n(\"entity\"<|>PKU<|>EVENT<|>Phenylketonuria (PKU) is a metabolic disorder that requires dietary management to prevent neurological damage.)\n##\n(\"entity\"<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>EVENT<|>Maple Syrup Urine Disease (MSUD) is an amino acid metabolism disorder characterized by a deficiency in the branched-chain alpha-keto acid dehydrogenase complex.)\n##\n(\"entity\"<|>LEUCINA<|>PERSON<|>Leucine is a branched-chain amino acid that is neurotoxic in high concentrations and is involved in metabolic pathways related to MSUD.)\n##\n(\"entity\"<|>ISOLEUCINA<|>PERSON<|>Isoleucine is a branched-chain amino acid that is part of the metabolic pathways associated with MSUD.)\n##\n(\"entity\"<|>VALINA<|>PERSON<|>Valine is a branched-chain amino acid that is involved in the metabolic pathways related to MSUD.)\n##\n(\"relationship\"<|>LNAA<|>PKU<|>LNAA is a therapeutic option for managing PKU, particularly for patients with poor dietary adherence.<|>8)\n##\n(\"relationship\"<|>PKU<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>PKU and MSUD are both metabolic disorders that involve amino acid metabolism and require dietary management.<|>7)\n##\n(\"relationship\"<|>LEUCINA<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>Leucine is one of the branched-chain amino acids that are implicated in MSUD, making it relevant to the disease.<|>6)\n##\n(\"relationship\"<|>ISOLEUCINA<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>Isoleucine is another branched-chain amino acid involved in the metabolic pathways associated with MSUD.<|>6)\n##\n(\"relationship\"<|>VALINA<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>Valine is also a branched-chain amino acid that plays a role in the metabolism related to MSUD.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: LNAA, disminuye el paso de Phe al cerebro.\n\nEsta opción terapéutica es más eficaz en aquellos pacientes con mala adherencia a la dieta10, 12.\n\nEs necesario investigar sobre la composición óptima de LNAA, efectos secundarios a largo plazo y beneficio a largo plazo en PKU.\n\nLa dosis en adultos es de 18 g/día. Útil en adultos y ancianos con PKU8.\n\n#### 2.6.4. Terapia génica\n\nSon numerosas las investigaciones que, durante los últimos años, se vienen realizando acerca de la terapia génica en la PKU.\n\nDicha terapia está basada en la introducción de un gen PAH funcional en células del paciente y en la expresión de la enzima hepática en tejido heterólogo como el músculo.\n\nRecientemente se ha demostrado una corrección efectiva duradera en ratones, mediante la inyección intramuscular de un sistema completo de hidroxilación de Phe, que incluye el gen PAH y dos genes esenciales para la síntesis de BH49.\n\n### 3. Enfermedad de orina de jarabe de arce\n\n#### 3.1. Consideraciones generales\n\nLa enfermedad de orina de jarabe de arce (EOJA; Maple syrup urine disease, MSUD) es una aminoacidopatía del metabolismo de los aa de cadena ramificada (leucina, valina e isoleucina; branched chain aminoacids, BCAA) como consecuencia de un déficit enzimático del complejo deshidrogenasa (figura 2).\n\nEs una enfermedad autosómica recesiva con una incidencia de 1/250000 recién nacidos vivos. Se distinguen cinco fenotipos clínicos y bioquímicos diferentes (clásica, intermedia, intermitente, sensible a tiamina y deficiencia del componente E3 del complejo multienzimático deshidrogenasa), pero de forma práctica en la clínica podemos distinguir la forma neonatal (se manifiesta como un cuadro tóxico en el neonato), la forma intermedia (se presenta con fallo de medro y retraso psicomotor, ataxia y convulsiones) y la forma del adulto (sin clínica característica y que suele presentarse como crisis de ataxia, convulsiones y cetoacidosis coincidiendo con procesos intercurrentes).\n\nEl diagnóstico se realiza mediante determinación de aa en sangre (presencia patognomónica y característica de aloisoleucina) y se confirma con la determinación del déficit enzimático en biopsia de piel y/o el estudio mutacional.\n---\nTema 18. Soporte nutricional en metabolopatías de los aminoácidos... 311\n\n```mermaid\ngraph TD\n    A[Leucina] --> B[Ác. α-isocaproico]\n    C[Isoleucina] --> D[Ác. α-ceto-β-metilvalérico]\n    E[Valina] --> F[Ác. α-cetoisovalérico]\n    \n    B --> |Complejo multienzimático deshidrogenasa (MSUD)| G[Isovaleril-CoA]\n    D --> |Complejo multienzimático deshidrogenasa (MSUD)| H[α-metilbutiril-CoA]\n    F --> |Complejo multienzimático deshidrogenasa (MSUD)| I[Isobutiril-CoA]\n    \n    G --> |Isovaleril-CoA Deshidrogenasa (Acidemia isovalérica)| J[Acetoacetato]\n    G --> |Isovaleril-CoA Deshidrogenasa (Acidemia isovalérica)| K[Acetil-CoA]\n    \n    K --> L[Propionil-CoA]\n    L --> |Propionil-CoA carboxilasa (Acidemia propiónica)| M[Metilmalonil-CoA mutasa (Acidemia metilmalónica)]\n    M --> N[Succinil-CoA]\n```\n\nFigura 2. Vías metabólicas de los aminoácidos ramificados y metabolopatías asociadas.\n\n### 3.2. Tratamiento dietético en la fase aguda\n\nTiene como objetivo inducir el anabolismo y evitar el catabolismo proteico para conseguir disminuir las cifras de los tres BCAA, en especial de la leucina, que es el más neurotóxico. Para ello, disponemos de varias posibilidades:\n\na. Instaurar nutrición parenteral con una mezcla de aa exento de BCAA (no disponible en España) y un alto contenido energético con glucosa e insulina si fuera necesario.\nb. Instaurar nutrición enteral continua con una fórmula exenta de BCAA.\nc. Nutrición enteral continua con una fórmula diluida y suplementada con polímeros de glucosa.\n\nSi la concentración plasmática de los BCAA desciende por debajo de valores normales, sería necesario iniciar un suplemento (100-200 mg/día y 50-100 mg/día para valina e isoleucina, y leucina respectivamente).\n\n### 3\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}